14NER Oncology, Inc.
Records under this name other than the patents 14NER Oncology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 2 of 2 · Back to 14NER Oncology, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,518,130 | Use of ERBB3 Inhibitors in the Treatment of Triple Negative and Basal-Like Breast Cancers Lapsed on the fee record Ended Dec 13, 2024 · High confidence | Lapsed on the fee record | Ended Dec 13, 2024 | High confidence |
| US 8,895,001 | Use of ERBB3 Inhibitors in the Treatment of Triple Negative and Basal-Like Breast Cancers Lapsed on the fee record Ended Nov 25, 2022 · High confidence | Lapsed on the fee record | Ended Nov 25, 2022 | High confidence |